2019 Agency of the Year

4 leaders start 2016 with promotions

Dudnyk President Christopher Tobias, PhD, announced that Laurie Bartolomeo, John Kemble, and Drew Desjardins were promoted from senior vice presidents to executive vice presidents. Dan Zaksas, PhD, was promoted to Senior Vice President, Director of Medical and Scientific Affairs.

“It is my pleasure to recognize the personal and professional growth achieved by Laurie, John, Drew, and Dan,” said Tobias. “Their dedication over the years to our clients and colleagues has driven Dudnyk’s laser focus on creating motivating brand experiences for specialty physicians and their patients, and has helped to fuel Dudnyk’s phenomenal growth."

The collaboration between Laurie Bartolomeo, EVP, Creative Director, and John Kemble, EVP, Creative Director, began in 2006 with Laurie’s return to Dudnyk after a 4-year hiatus. Their early partnership, with Laurie writing copy and John supplying the visuals, produced award-winning work for many of Dudnyk’s clients. Laurie’s strength is in her ability to take her conceptual vision of each brand and weave it into a creative strategy that is targeted, differentiating, and effective. John is a creative visionary with more than 20 years in the industry. He brings a wealth of knowledge and talent to Dudnyk’s process as he guides the creative team to deliver powerful brand experiences across all channels.

Later as associate creative directors and more recently as Dudnyk’s creative directors, Laurie and John continually push their department to turn each client’s key insight into behavior-changing campaigns for specialty physicians and their patients. Laurie and John’s passion for breakthrough creative resulted in Dudnyk being named in 2014 as Agency of the Year by Medical Marketing & Media and as the Most Creative Agency in the healthcare communications industry by Med Ad News.

Drew Desjardins, EVP, Chief Strategy Officer, knows how to launch brands of all sizes from both the client and the agency sides. Over a span of two decades at Wyeth and Pfizer, Drew led the marketing team responsible for the mega-brand launch of Pristiq and provided strategic leadership to guide the brand evolution of Protonix. Drew’s first experience with orphan drugs was when he spearheaded efforts to have Cordarone I.V. included in the Advanced Cardiac Life Support (ACLS) guidelines. By changing the standard of care paradigm, Drew and his team were able to build Cordarone I.V. into a $250MM brand, which exceeded peak sales projections by ten-fold.

Drew joined the Dudnyk team in 2011 to provide strategy guidance to the agency’s clients and business development activities. He strengthened agency strategic deliverables by implementing new processes and tools. Working closely with Dudnyk’s account services, creative, and medical and scientific affairs teams, Drew helps clients determine the best strategies and tactics to achieve their business goals. Drew’s strategic talents have been instrumental in growing the agency through new business acquisition and organic growth.

Dan Zaksas, PhD, SVP, Director of Medical and Scientific Affairs, provides scientific guidance and medical strategy across the full spectrum of products and therapeutic areas at Dudnyk. He oversees the education of internal teams on each product's clinical nuance and competitive landscape, brings medical and scientific credibility to creative concepts, and dives headfirst into research to find the nugget of information that will help pull together a truly unique brand position. With a mind for both marketing excellence and scientific rigor, Dan helps clients build successful brands while ensuring that all materials are medically accurate and strategically sound. Since starting in 2011 as Dudnyk’s scientific director, Dan has grown the department and integrated it with all facets of the agency. The result is a stronger scientific presence in business development efforts and the building, strengthening, and enhancement of relationships with clients on both the commercial and clinical sides of their businesses.